Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Sovihep V - 12 weeks


Availability: In stock

Special Price $ 825

BRAND : Sovihep V
STRENGTH : 400 mg & 100 mg
INGREDIENT : HepatitisC-Zydus-velpatasvir-100mg-Sofosbuvir-400mg-Sovihep-V
COUNT : 28 Tablets

Description of Sovihep V - 12 weeks

Product Index: Brand name: Sovihep V Active component: Sofosbuvir and Velpatasvir Strength of the components: 400mg and 100mg respectively Mfg: Zydus Cadila Package: 28 tablets in a container Category: Anti-viral Description – 12 weeks Sovihep V is a fixed dose combination drug, contains Sofosbuvir and Velpatasvir as an active ingredients. Both the components exhibit anti-viral activity. Sovihep V is a prescription medicine; it is taken by the patients only under the guidance of medical practitioner Sovihep V tablet is active against virus which causes hepatitis C infection in adults Sovihep V contains; Sofosbuvir-HCV NS5B polymerase inhibitor Velpatasvir-HCV NS5A inhibitor

Pharmacology of Sovihep V - 12 weeks

Mechanism of action: 12 weeks Sovihep V – Treatment for chronic hepatitis C viral infection for 12 weeks Sofosbuvir is one of the component of Sovihep V tablet, is an HCV NS5B RNA polymerase inhibitor This undergoes intracellular metabolism to form uridine analogue triphosphate Inhibition of viral multiplication occurs by incorporating into HCV RNA and acts as a chain terminator Velpatasvir HCV NS5A protein inhibitor, it blocks the protein activity and inhibits viral multiplication. Pharmacokinetic: 12 weeks Absorption: The Sovihep V tablet was quickly absorbed after oral administration. The peak plasma concentration of both component in Sovihep V and active metabolite of Sovihep V (GS-461203) occurs within 1 hour, 3 hours, and 3 hours respectively Distribution: Food does not interfere with Sovihep V action Sofosbuvir, Plasma protein binding: 61-65% Velpatasvir, plasma protein bound: >99.5% The active metabolite of the tablet Sovihep V has poor protein binding property. Metabolism: Sofosbuvir is metabolized in liver, changed to active analogue triphosphate GS-461203 Elimination: 80% metabolite eliminated: urine; 14% of metabolites: faeces; 2.5%: exhaled air The terminal half life of Sovihep V tablet is 15 hours

Indication of Sovihep V - 12 weeks

Sovihep V is mainly indicated for the patients who are suffered with chronic hepatitis C viral infection associated genotype I, II, III, IV, V or VI infection. Generally Sovihep V tablets are taken for 12 weeks, it may effective in patients. Types of hepatitis Without cirrhosis or with compensated cirrhosis With decompensated cirrhosis with use of ribavirin

Dose & Dosage's of Sovihep V - 12 weeks

Sovihep V is recommended for adults. The safety and efficacy of the drug has not been established for children. Chronic hepatitis C virus (HCV) infection genotypes I, II, III, IV, V or VI One tablet to be taken as a single dose Sovihep V should be taken with or without food Compensated cirrhosis (child Pugh A): Take Sovihep V tablet for 12 weeks Decompensated cirrhosis (child Pugh B or C) should take as combination of Sovihep V and ribavirin for 12 weeks The dose of ribavirin recommended on the basis of weight of patient; <75 kg: 1000mg/day twice daily ≥75 kg: 1200mg/day twice daily The dosage of ribavirin should be decreased on the basis of hemoglobin and creatine clearance levels. Missed dose: If patient missed the dose of Sovihep V tablet, should be skipped and follow the next dose schedule. Consult the physician for further details Do not take double dose

Side Effects of Sovihep V - 12 weeks

Patients Without cirrhosis Headache, fatigue, shortness of breath, chest pain Patients With decompensated cirrhosis Fatigue, anemia, decreased hemoglobulin levels, nausea, headache, insomnia 1-10% of patients attain; Patients Without cirrhosis; Lipase increase, rash, depression, increased creatine kinase, insomnia, asthenia Patients With decompensated cirrhosis; Diarrhea, hemoglobin levels get depleted, rash, increased creatine kinase Common side effects: Headache, unusual tiredness, chest pain, swelling of peripheral organs, skin rashes, breathing trouble Post marketing reports: angioedema

Contraindication of Sovihep V - 12 weeks

Sovihep V while combining with ribavirin for advanced cirrhosis, in this condition it is contraindicated to the pregnant women and women who become pregnant, ribavirin cause harm to the fetal

Drug Interaction of Sovihep V - 12 weeks

While taking Sovihep V for 12 weeks, some of the drugs should not taken in combination; Ant acids: aluminium hydroxide, magnesium hydroxide, calcium carbonate H2 receptor antagonist: famotidine, ranitidine, Cimetidine Proton pump inhibitors: Omeprazole, esomeprozole, pantoprazole, lansoprazole Anti-arrhythmic: amiodarone, digoxin Anti-cancer: topotecan Anti-mycobacterials: rifabutin, rifampin, rifapentine HIV antiretroviral: efavirenz, tenofovir, tipranavir ritonavir Herbal supplements: st. Johns wort Anti convulsants: carbamazepine, phenytoin, Phenobarbital, oxcarbazepine HMG CoA reductase inhibitors: rosuvastatin, Atorvastatin

Precaution of Sovihep V - 12 weeks

Risk of HBV reactivation in patient co infected with HCV and HBV Co administration of amiodarone with Sovihep V causes bradycardia; caution should be taking while combining with amiodarone Caution with use in Liver and kidney impairment patients

Usage & Safety profile of Sovihep V - 12 weeks Pregnancy & Lactation

Sovihep V with ribavirin is not safe to use in pregnancy condition, it may leads to fetal death Breast feeding is not recommended

Storage of Sovihep V - 12 weeks

Storage: Sovihep V should be stored at room temperature. Sovihep V tablet container should be keep away from moisture, heat, and light